Imatinib mesylate (Gleevec, STI571), an inhibitor of ABL, PDGFRα, and KIT tyrosine kinases, is successfully applied to the treatment of BCR-ABL-positive chronic myelogenous leukemia (CML) [11]. This evidence concerns the gene PDGFRA and chronic myelogenous leukemia, BCR-ABL1 positive.